GlassScriptPhysician profile
Christian Leblanc
NPI 1689115966
$11,632.68
in general payments reported to CMS, 2019-2025
40 companies · $2,166 in 2025
The $2,166 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.64 · 2020: $366 · 2021: $2,427 · 2022: $2,310 · 2023: $2,148 · 2024: $2,204 · 2025: $2,166.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,518.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,518.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,212.23 | 2021-2025 | |
| Novo Nordisk INC | $1,394.02 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $1,322.79 | 2020-2025 | Repatha, Otezla, Evenity |
| Astrazeneca Pharmaceuticals LP | $842.29 | 2020-2025 | Breztri, Airsupra, Farxiga |
| Lilly USA, LLC | $832.36 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $760.45 | 2021-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Pfizer INC. | $518.86 | 2023-2025 | |
| Sumitomo Pharma America, INC. | $396.20 | 2023-2025 | Gemtesa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $329.03 | 2020-2024 | Jardiance, Synjardy, Ofev |
| Esperion Therapeutics, INC. | $315.06 | 2020-2024 | Nexletol |
| Astellas Pharma US INC | $294.00 | 2023-2025 | Veozah, Myrbetriq |
| Amarin Pharma, INC. | $241.68 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $230.82 | 2020-2025 | Gardasil 9, Capvaxive, Verquvo |
| Novartis Pharmaceuticals Corporation | $216.41 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $187.62 | 2020-2025 | Trintellix |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christian Leblanc listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.